Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch table for November 2013

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during November 2013.

For an indepth analysis of these deals, read 'Pharma deals during November 2013'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

Viropharm / Shire
AcquisitionOrphan drugs including Cinryze for prophylactic
treatment of hereditary angioedema
4,200
Santarus / Salix
Acquisition
Portfolio of approved products in GI, diabetes and
Hyperlipidemia
2,600
Algeta / Bayer
AcquisitionBuys out deal for Xofigo radiotherapeutic for
prostate cancer
2,400
Pfizer / LillyCo-developmentShared development of tanezumab (anti-nerve growth factor) for the treatment of osteoarthritis, chronic low back and cancer pain
1,800
Novartis / Grifols
AcquisitionNovartis divestment of its blood transfusion testing unit
1,675
Paladin / Endo Health
AcquisitionPortfolio includes products in attention deficit
hyperactivity disorder, pain, urology and allergy
1,600
immatics / Roche
R&D and
commercialisation
IMA942 tumour-associated peptide cancer vaccine candidates in NSCLC and prostate cancer
1,017
Patheon / Royal DSM and JLL Partners
Merger and acquisition
DSM and JLL Partners (private equity) acquire
Patheon and merge it with DSM's CMO Pharmaceutical Products Division in a jointly owned Newco
582
Polyphor / Roche
Licence
POL7080 which targets Pseudomonas aeruginosa, completed phase I
548
Cytori/Lorem
Vascular
Licence
Cell therapy for CVS, diabetes, and renal disease
includes equity purchase
531
Vital Signs/
CareFusion
AcquisitionVital Signs is the respiratory care and anesthesiology product manufacturer division of GE Healthcare
500
Clovis / Servier
Licence
Servier licenses lucitanib excluding China, Japan and the US
475
Egalet /ShionogiLicenceOral abuse-deterrent hydrocodone opioid products includes an equity purchase
425
EOS /ClovisAcquisitionLucitanib for FGF aberrant breast cancer
420
BeiGene / Merck
Serono
Co-development
Expansion of collaboration to include BeiGene 290 for cancer
232
Cell Therapeutics / Baxter
Licence
JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase
172
Vertex / Janssen
Royalty sale
Sale of product royalty rights relating to INCIVO (telaprevir) to Janssen Pharmaceutica
152
Calidus / AmicusAcquisitionPurchase of Callidus' late-stage enzyme replacement therapy for Pompe disease 130
Evotec /JanssenR&D collaboration
Target AD collaboration to identify novel therapies for Alzheimer's 125
Merck & Co / AkornProduct acquisition
US rights to AzaSite, Cosopt, Cosopt PF ophthalmic products 52.8


 

The Deal Watch table is compiled by Medius Associates

13th December 2013

The Deal Watch table is compiled by Medius Associates

13th December 2013

From: Research, Sales

Share

Tags


Career advice

No results were found

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Infographics